AC-SDKP Goralatide Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 3-day acute treatment window; no validated recurring cycle format
• Frequency: Six to nine subcutaneous injections across the 3-day window (roughly twice to three times daily)
• Common delivery routes: Subcutaneous injection; continuous subcutaneous infusion (research setting)
• Key timing notes: The 48-hour pre-treatment lead time is the single most critical timing variable; starting less than 48 hours before the stressor significantly reduces protective effect

Who This Protocol Is For

AC-SDKP Goralatide draws interest from a narrow but specific group: those looking at bone marrow protection in the context of hematopoietic stress, researchers and practitioners exploring anti-fibrotic peptides for cardiac and renal tissue, and a smaller group investigating the compound's anti-inflammatory properties in acute injury scenarios. The compound is structurally derived from the N-terminus of Thymosin Beta-4, which places it in the same general family as TB-500, but its mechanism and research context are meaningfully different.

Most of the research centers on a specific protective application: shielding hematopoietic stem cells (the cells in bone marrow that produce all blood cell types) from the damage caused by agents that target rapidly dividing cells. Within that context, the primary research goal is preserving the most primitive stem cell populations so they can reconstitute normal blood production after the stressor has passed. A secondary research interest covers the compound's anti-fibrotic activity in cardiac and renal tissue, particularly following injury, and its pro-angiogenic (blood vessel-forming) properties that may support tissue repair.

Goralatide's validated protocol is a precise short-window event tied to a specific biological context. It keeps hematopoietic stem cells in a quiescent (resting, non-dividing) state before a damaging event, which is a fundamentally different objective from a general health stack or a multi-week wellness cycle. Understanding the timing requirements and the compound's inhibitory mechanism is essential before approaching any protocol. Preferred delivery is subcutaneous injection, the only route covered in the research literature, so route preference does not create the same optionality it does for some other peptides.

How Is an AC-SDKP Goralatide Cycle Structured?

A Goralatide protocol does not follow the recurring on-off cycle shape common to most wellness peptides. Where a compound like TB-500 or BPC-157 is typically run for several weeks at a steady frequency, Goralatide's validated use is a single acute event: a 3-day treatment window built around a specific timing anchor.

The structure begins with a pre-treatment phase that starts 48 hours before the hematopoietic stressor. This is not a loading phase in the traditional peptide sense. Instead, the 48-hour lead time is a biological necessity: the compound needs sufficient time in the system to shift hematopoietic stem cells into a quiescent, resting state before the stressor arrives. Think of it as setting a biological lock on the cells you want to protect before the disruption hits. Administration then continues through the stressor window and for approximately 24 hours afterward, completing a 72-hour coverage period. There is no established maintenance phase that follows.

What this means in practice is that the cycle architecture is fundamentally different from anything in the standard wellness peptide toolkit. General cycling schedules of several weeks on followed by a break period are not validated for this compound and do not fit its mechanism. The Loading and Maintenance Phases section below covers the specifics of what the 3-day window looks like in practice.

All protocol data for this compound comes from preclinical animal models. No approved human clinical trials with established dosing protocols have been published, which is worth understanding before approaching this compound.

How Your Dose Is Determined

What moves an AC-SDKP Goralatide dose:

• Your goal: The research literature distinguishes between bone marrow protection and anti-fibrotic or anti-inflammatory applications. The protective hematopoietic context is the one with the clearest protocol structure, and the dose threshold matters significantly here: research shows a clear boundary between doses that produce measurable stem cell quiescence and doses that are too low to generate a protective effect. Anti-fibrotic and anti-inflammatory applications operate in a separate dose context. The goal determines which part of the studied range is relevant.
• Experience level: Because this compound is experimental, someone approaching it for the first time typically works within the more conservative end of what the research models suggest, while someone with a clearer clinical picture may work with a practitioner to calibrate more precisely.
• Delivery route: Subcutaneous injection is the only route covered in the research. Continuous subcutaneous infusion has also been studied and produced equivalent protective outcomes to fractionated injections across the same 72-hour window. The route shapes how the dose is distributed across the treatment window rather than the total amount in isolation.
• Individual response: Research demonstrates a clear dose-response relationship, with lower doses producing negligible protective effect and higher doses producing a pronounced one. Where an individual lands within the effective range depends on factors a practitioner assesses case by case.

The dose picture for Goralatide is genuinely different from most peptides in this library. There is no long-established community consensus on a weekly maintenance dose, and the threshold between an ineffective dose and an effective one appears meaningful rather than gradual, which makes calibration more consequential here than with many other compounds. The actual dose for a human protocol requires individual calibration, which is exactly what the app is built to handle.

Get your protocol at mypeptidepal.ai

How Often Do You Take AC-SDKP Goralatide?

Frequency is one of the most research-defined aspects of a Goralatide protocol, and the findings are unusually specific. Single-injection and three-injection approaches produced significantly weaker protective outcomes in preclinical research compared to protocols using six to nine administrations across the 3-day window. The relationship between dose frequency and outcome is not just about total amount delivered; it is about maintaining sufficient compound presence across the critical pre-treatment period.

The two most effective frequency patterns are six injections across 3 days, roughly twice daily, and nine injections across 3 days, roughly three times daily. Both produced equivalent best-case outcomes in the research models. Continuous subcutaneous infusion across the same 72-hour period also achieved equivalent results, suggesting that sustained exposure is the key driver rather than any specific injection count. Some protocols split the daily administrations into morning and evening windows to achieve that sustained presence.

Timing relative to the hematopoietic stressor is the single most important variable this compound has. The 48-hour pre-treatment lead time is not a general guideline; starting only 24 hours before the stressor does not produce significant protective benefit. Administration begins at the 48-hour mark, continues through the stressor, and extends approximately 24 hours beyond it.

For anti-inflammatory or anti-fibrotic applications, the timing context differs. In spinal cord injury research using a rat model, administration began within 2 to 6 hours of injury and continued once daily for 7 days. This is a distinct protocol shape from the chemotherapy-protection context and reflects the different biological objectives of those two applications.

Loading and Maintenance Phases

Goralatide does not follow a conventional loading-then-maintenance structure, and understanding why matters for anyone approaching this compound.

In a typical wellness peptide protocol, a loading phase front-loads consistent early use to build compound levels before settling into a steady lower maintenance dose. Goralatide's 3-day pre-treatment window serves a different purpose entirely: it is about achieving and sustaining sufficient stem cell quiescence before a specific event, not about receptor saturation or building a steady-state level. The dose stays consistent across the treatment window rather than stepping down after an initial period, because the goal is uninterrupted protective coverage, not a phase transition.

The most effective structure is six to nine subcutaneous injections distributed across 72 hours, beginning 48 hours before the stressor and continuing through and just beyond it. Continuous subcutaneous infusion across the same window produced equivalent outcomes. After the treatment window closes, there is no validated maintenance phase: the literature does not describe a follow-on dosing period, and applying a generic maintenance framework from other peptide protocols would be extrapolating beyond what the research supports.

For bone marrow recovery following the stressor, research shows that combining Goralatide pre-treatment with G-CSF (Granulocyte Colony-Stimulating Factor) during the recovery period significantly enhances reconstitution of CFU-GM (the blood-forming progenitor cells that rebuild normal blood production after damage). Omitting G-CSF from the post-treatment phase leaves a meaningful portion of the protocol's potential benefit unrealized. This combination aspect is worth understanding as part of the full protocol picture, even though G-CSF is a separate compound with its own administration requirements.

Off-Cycle Considerations

There is no established off-cycle break duration for Goralatide, because the protocol itself is not a recurring cycle. The validated use in research is a single acute treatment event, not a repeating schedule. This distinguishes Goralatide clearly from peptides like BPC-157 or GHK-Cu, where a typical cycle runs for several weeks and is followed by a structured break before repeating.

The absence of an off-cycle framework reflects the nature of the compound's primary application in research. When Goralatide is used in the context it has been studied for, the question of when to take a break does not arise in the same way it does for a weekly wellness protocol.

For people exploring Goralatide's anti-fibrotic or anti-inflammatory properties over a longer timeframe, such as the 7-day once-daily structure from the spinal cord injury model, what follows that window is genuinely unanswered by the existing literature. Standard cycling heuristics from other compound classes do not transfer directly to a compound with an inhibitory mechanism acting on stem cell proliferation. Working with a practitioner who understands the compound's biology is the appropriate path for anyone considering extended or repeated use.

What to Expect Week by Week

Because Goralatide's validated protocol is a 3-day acute event rather than a multi-week cycle, the standard week-by-week framework does not map neatly here. What the research covers is a timeline measured in hours.

• Hours 0 to 8: At sufficient concentration, research shows the compound begins shifting hematopoietic stem cells toward a quiescent state within approximately 8 hours of exposure. This is a cellular-level biological process, not something observable in daily function.
• Hours 0 to 48 (pre-treatment window): The full pre-treatment period is the phase during which stem cell quiescence is established. By the time the stressor arrives, a well-run protocol has had sufficient time to generate meaningful protective effect on the target cell populations.
• Hours 48 to 72 (stressor window and immediate follow-through): Administration continues through and just beyond the stressor. The protective effect on long-term reconstituting stem cells and CFU-GM (the blood-forming progenitor cells that rebuild normal blood production after damage) populations is the primary outcome being established during this window.
• Post-treatment recovery: When Goralatide pre-treatment is followed by G-CSF during the recovery period, research shows significantly improved reconstitution of hematopoietic cell populations compared to either agent used alone. This recovery unfolds over days to weeks depending on the severity of the initial stressor.

What a well-run Goralatide protocol looks like when it goes right: in mouse models, a carefully timed, adequately dosed, fractionated protocol produced mean survival times of up to 60 days, compared to significantly shorter outcomes in untreated controls or single-dose groups. That gap between a precisely structured six-to-nine injection approach and a single-injection attempt is one of the clearest dose-frequency findings in the peptide research literature. The compound does what it does when the timing and frequency are right; the precision of the protocol structure is the variable that separates meaningful protection from negligible effect.

General peptide therapy timelines describing subjective changes across weeks 1 through 12 are derived from compounds with stimulatory or tissue-repair mechanisms and do not apply here. It is worth being clear-eyed about that distinction rather than importing expectations from a different class of compound.

Common Protocol Mistakes

Starting the pre-treatment window too late. The 48-hour lead time is the single most important timing variable in this protocol. Research is specific: starting administration only 24 hours before the hematopoietic stressor does not produce significant protective benefit. Compressing the pre-treatment window undermines the entire protocol's purpose.

Using too few injections. Single-injection and three-injection approaches are significantly less effective than six-to-nine injection protocols across the 3-day window. It is not just about the total amount delivered; it is about maintaining sufficient compound presence throughout the pre-treatment period. Opting for fewer injections because they are simpler misses a core finding from the research.

Assuming low doses are sufficient. The research shows a clear dose threshold below which protective effects are negligible. Doses at the low end of the tested range produced no meaningful CFU-GM recovery. This is a compound where falling below the effective threshold appears to produce near-zero benefit rather than partial benefit, which makes calibration to the appropriate range more consequential than with some other peptides.

Applying generic wellness peptide cycling schedules. Goralatide is not a compound to run on a 5-days-on, 2-days-off schedule or a 12-week cycle. Its mechanism is inhibitory rather than stimulatory, and its validated protocol is a short acute event. Importing cycling logic from growth hormone secretagogues or tissue-repair peptides is not supported by the research.

Omitting G-CSF from the post-treatment protocol. In the chemotherapy-protection context, Goralatide pre-treatment followed by G-CSF during recovery produces significantly better reconstitution of hematopoietic cell populations than Goralatide alone. Using Goralatide without accounting for the post-treatment recovery phase leaves a substantial portion of the protocol's studied benefit unrealized.

Sourcing from unverifiable suppliers. Because Goralatide is not an approved pharmaceutical product for human use, it is available only through research peptide suppliers. Product quality, purity, and accurate dosing depend entirely on the supplier's manufacturing standards, independent testing, and traceability practices. Sourcing from suppliers who cannot document their manufacturing standards or provide third-party testing introduces meaningful uncertainty into any protocol.

AC-SDKP Goralatide is not FDA-approved for human therapeutic use and is classified as an experimental compound. Athletes in tested sports should verify current WADA status independently before use.

Frequently Asked Questions

How long is a typical AC-SDKP Goralatide protocol?

The validated protocol structure in research is a 3-day acute treatment window, not a multi-week recurring cycle. Administration begins 48 hours before the target event and continues through and just beyond it, covering approximately 72 hours total. There is no established recurring cycle format for this compound, which makes it fundamentally different in structure from most wellness peptides.

How often do you take AC-SDKP Goralatide?

Research points to six to nine subcutaneous injections distributed across the 3-day treatment window as the most effective frequency pattern, working out to roughly twice or three times daily. Single-injection and three-injection protocols produced significantly weaker outcomes in preclinical research. Continuous subcutaneous infusion across the same 72-hour window achieved equivalent results to the six-to-nine injection approach.

Does AC-SDKP Goralatide need a loading phase?

Not in the conventional sense. The 48-hour pre-treatment window serves a different purpose from a traditional loading phase: it is about establishing stem cell quiescence before the hematopoietic stressor arrives, not about saturating receptors or building a steady-state compound level. The dose stays consistent across the treatment window rather than stepping down after an initial period.

Do you need to cycle off AC-SDKP Goralatide?

Because the validated protocol is a single acute treatment event rather than a recurring cycle, the concept of an off-cycle break does not apply in the same way it does for most wellness peptides. There is no established off-cycle duration in the research. Anyone exploring extended or repeated use for anti-fibrotic or anti-inflammatory applications is working beyond what the current literature has validated and should do so with appropriate clinical guidance.

What makes AC-SDKP Goralatide different from TB-500?

Despite sharing structural origins in Thymosin Beta-4, the two compounds have meaningfully different mechanisms and research contexts. TB-500 is primarily associated with tissue repair and recovery through actin regulation and pro-healing activity. Goralatide's primary mechanism is inhibitory: it prevents hematopoietic stem cells from entering the active division phase of the cell cycle, which is the basis for its bone marrow protection research. The protocols, timing requirements, and expected effects differ substantially between them.

Can AC-SDKP Goralatide be used for anti-fibrotic purposes?

Preclinical research covers anti-fibrotic activity in cardiac and renal tissue, with evidence of reduced organ fibrosis following injury in animal models. Because ACE inhibitors elevate endogenous Ac-SDKP levels, the compound is believed to contribute to some of the cardioprotective and renoprotective effects associated with that drug class. Human clinical data for anti-fibrotic applications remains limited, and protocols for this purpose are less defined than the chemotherapy-protection context.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for AC-SDKP Goralatide in one place.